Advanced ImmunoChemical, Inc.

VENENUM Biodesign is focused on discovering and advancing innovative new medicines for significant unmet medical needs in key therapeutic areas, including; cancer, inflammation, infectious diseases, metabolic diseases, and women’s health. Our most advanced programs are targeting Clostridium difficile infection (CDI) and Type 2 Diabetes (T2D).

Our business model allows us to focus on the creation of high value, innovative small molecule programs against well-validated targets, as well as new targets identified from our own research and to work with partners for clinical and commercial development to bring our products to patients.

Our mission is to improve patients’ lives through the discovery of therapeutic compounds against our novel biological targets. Many of our targets involve novel protein-protein or protein-DNA interactions. Others are more conventional target classes e.g., GPCRs and enzymes. Our goal is to advance our discoveries to medicine through partnership with pharmaceutical companies.

We utilize state-of-the-art assay development and ultra-high throughput screening (UHTS) against our proprietary 6 million ECLiPS compound collection in conjunction with protein engineering and structural biology, medicinal chemistry, and in vivo models.

Invivotek LLC, a member of Genesis Biotechnology Group® (GBG) is a global pre-clinical contract research organization (CRO) specializing in small animal studies for drug discovery and early optimization. Invivotek's facility was opened in 2012 and our first commercial project launched in 2013.

Invivotek offers both custom and standard pre-clinical services for drug discovery and development programs for our clients. Invivotek’s portfolio includes animal models and bioassays designed to support in vivo testing of compounds related to Immunology and Inflammation, Oncology, Metabolic, and Cardiovascular diseases. Invivotek’s in vivo testing capabilities are supported by biochemical and molecular biology techniques as well as functional assays with primary cell cultures established from various mouse tissues under disease model and normal conditions. These assays provide tools to study the mechanism of action of various test therapeutics or potential target genes and to explore drug efficacy biomarkers. The collective experience across multiple therapeutic areas in conjunction with the business and project management skills of the team working in a state-of-the-art animal facility, position Invivotek as a leading provider of preclinical in vivo services.

Eurofins Scientific is an international life sciences company, providing a unique range of analytical testing services to clients across multiple industries, to make life and the environment safer, healthier and more sustainable. From the food you eat to the medicines you rely on, Eurofins works with the biggest companies in the world to ensure the products they supply are safe, their ingredients are authentic and labelling is accurate. Eurofins is a global leader in food, environmental, pharmaceutical and cosmetic product testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies.

In over just 30 years, Eurofins has grown from one laboratory in Nantes, France to over 50,000 staff across a network of more than 900 independent companies in over 50 countries, operating more than 800 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing.

Eurofins is one of the fastest growing listed European companies. Since its IPO on the French stock exchange in 1997, Eurofins’ sales have increased by 35% each year (in compound average) to over EUR 4.5 billion in 2019.

Independent biotechnology consulting. All topics related to drug discovery in the therapeutic areas of oncology, cardiovascular, angiogenesis, and inflammation. Expertise in additional areas of Ophthalmology (diabetic retinopathy, macular degeneration) Assistance in research planning and protocols, contracts with academic and commercial laboratories, editing and preparation of manuscripts, grant applications, research strategy, protocols for cell based assays, pharmacodynamic assays, and biomarker studies.

Kinexus Bioinformatics Corporation maps and monitors the molecular communications networks of living cells for biomedical research into the diagnosis, prognosis and treatment of human diseases. In particular, the company tracks enzymes called protein kinases that control other proteins by carrying out their phosphorylation at regulatory sites known as phosphosites. Phosphosites act as on/off switches for proteins. Their malfunction has been linked to more than 400 human diseases, including cancer, cardiovascular disease, diabetes and inflammation.

Currently, Kinexus measures the presence and activation states of over 650 different protein kinases and other regulatory proteins and many of their phosphosites in cell and tissue specimens through our integrated platform of cell culture, protein microarray, immunoblotting, mass spectrometry and immunohistochemistry services.

These innovative proprietary services utilize unique and stringent screening methods to facilitate the discovery and validation of biomarkers, drug targets and the rapid exclusion of inappropriate drug leads in the early stages of the drug discovery process. This is further augmented by a suite of open source, online bioinformatics services that are offered by Kinexus. Our bioinformatics studies are helping us to create new tools for biomedical research that include enzymes, antibodies and peptides.

For over 12 years, Kinexus has provided our unique services to over 1600 laboratories in 35 countries.